Dr.Aishwarya Singh, Dr. Subhashree Das, Dr. Satya Mohapatra, Dr. Niranjan Sahu


Prostate cancer is most common malignancy in males in India. DRE and PSA are commonly used for clinical and biochemical evaluation of suspected patients. TRUS is the primary imaging modality for both benign and malignant disease.  In view of limitations of PSA, DRE and TRUS, MRI is the evolving modality. PIRADS refers to structured reporting scheme for evaluating prostate cancer. It is based on T2W and Diffusion weighted sequences along with Dynamic contrast enhanced scan which offers additional value for localisation of lesion. This study was done at a tertiary care centre in eastern India with total study population of 50 patients. Patients with DRE suspicious, negative TRUS guided biopsy and elevated PSA were included in the study. Most of the patients with PIRADS 4 and 5 came out to be proastatic adenocarcinoma showing high Gleason score in TRUS guided biopsy.


PIRADS,, Prostatic carcinoma, TRUS Biopsy, PSA, MpMRI

Full Text:



Trabulsi EJ, Sackett D, Gomella LG, Halpern EJ. Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer.Urology. 2010;76:1025–33. [PubMed]

Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907. [PubMed]

Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer. JUrol 143:742–746

Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture.Eur J Cancer 37(Suppl 8):S4–S66

Ahmed, H. U. et al. Is it time to consider a role of MRI before biopsy Nat. Rev. Clin.Oncol.6, 197–206 (2009); doi:10.1038/nrclinonc.2009.18

ikonen, s. et al. Magnetic resonance imaging of clinically localized prostatic cancer. J. Urol. 159, 915–919 (1998).

Zakian, K. L. et al. Correlation of proton Mr spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234, 804–814 (2005).

Hricak H, Choyk PL, Eberhardt S, LeibelSA,Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53.

Wang L. Incremental value of magnetic resonance imaging in the advanced management of prostate cancer. World J Radiol2009;31:3- 14.

Ingrid Mocikovaa, JozefBabelab, Vladimir Balazb Prostate cancer – the role of magnetic resonance imaging Biomed Pap Med FacUnivPalacky Olomouc Czech Repub. 2012 Jun; 156(2):103–107.

Morgan VA, Kyriazi S, Ashley SE, DeSouza NM. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.ActaRadiol. 2007 Jul: 48:695-703

Kozlowski, P. et al. Combined diffusion-weighted and dynamic contrast-enhanced Mri for prostate cancer diagnosis—correlation with biopsy and histopathology. J. Magn. Reson.Imaging2, 108–113 (2006).

Issa, B. (2002). "In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging." J MagnReson Imaging 16(2): 196-200.

Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T.J MagnReson Imaging. 2006 Feb: 23:130-4

Kim CK, Park BK, Han JJ, Kang TW, Lee HM. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. Journal of computer assisted tomography. 2007 May-Jun: 31:449-54

Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. European journal of radiology. 2007 Feb: 61:297-302

Kumar V, Jagannathan NR, Kumar R, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR in biomedicine. 2007 Aug: 20:505-11

Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, Hamm B: Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002; 224: 701–706.

Tamada, T., Sone, T., Jo, Y., Toshimitsu, S., Yamashita, T., Yamamoto, A., Tanimoto, D. and Ito, K. (2008). "Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade." J MagnReson Imaging 28(3): 720-6.

Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010; 16:1875–1883 [CrossRef] [Medline]

Scherr MK, Seitz M, Muller-Lisse UG, Ingrisch M, Reiser MF, Muller-Lisse UL. MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenatedimeglumine MRP parameters in detection of prostate cancer. Eur J Radiol 2010; 76:359–366 [CrossRef] [Medline]

Panebianco V, Sciarra A, Ciccariello M, et al. Role of magnetic resonance spectroscopic imaging ([(1)H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA). Radiol Med (Torino) 2010; 115:1314–1329 [CrossRef]

Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR 2007; 189:849; [web]W192–W201 [Abstract] [Medline]

Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J MagnReson Imaging 2005; 22:639–646 [CrossRef][Medline]

Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 1

TurkbeyB , Pinto P Mani H , Bernardo M , Pang Y , McKinney Y , Khurana K Ravizzini G , Albert P , Merino M , Choyke P , Prostate Cancer: Value of Multiparametric MR Imaging at 3 T for Detection—Histopathologic Correlation Radiology. 2010 April; 255(1): 89-99

:2432–2437 [CrossRef] [Medline]

Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257:715–723 [CrossRef] [Medline]


  • There are currently no refbacks.